Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque

Circulation Research

Volumn 103, Issue 10, 2008, Pages 1084-1091

  Shaw, James A ^a   Bobik, Alex ^a   Murphy, Andrew ^a   Kanellakis, Peter ^a   Blombery, Peter ^a   Mukhamedova, Nigora ^a   Woollard, Kevin ^a   Lyon, Stuart ^a   Sviridov, Dmitri ^a   Dart, Anthony M ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

Atherosclerosis; Inflammation; Lipoproteins

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN B; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PLACEBO; VASCULAR CELL ADHESION MOLECULE 1; CARDIOTONIC AGENT; FIBRINOLYTIC AGENT;

AGED; ANTIGEN EXPRESSION; ARTICLE; ATHERECTOMY; ATHEROSCLEROTIC PLAQUE; CELL SIZE; CLAUDICATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INFUSION; FEMALE; HEART PROTECTION; HISTORY; HUMAN; HUMAN TISSUE; MACROPHAGE; MALE; PLASMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SUPERFICIAL FEMORAL ARTERY; BLOOD; DIET THERAPY; GENE EXPRESSION REGULATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED;

AGED; ASPIRIN; CARDIOTONIC AGENTS; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; FEMALE; FIBRINOLYTIC AGENTS; GENE EXPRESSION REGULATION; HUMANS; INFUSIONS, INTRAVENOUS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; VASCULAR CELL ADHESION MOLECULE-1;

EID: 58149153296     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.182063     Document Type: Article

References (33)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. 2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22. (Pubitemid 34756487)
3. 3.PekkanenJ,LinnS,HeissG,SuchindranCM,LeonA,RifkindBM,TyrolerHA. Ten-yearmortalityfromcardiovasculardiseaseinrelation- cholesterollevelamongmenwithandwithoutpreexistingcardiovasculardisease. NEnglJMed.1990;322:1700-1707.(Pubitemid20231527)
4. Boden WE High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol. 2000;86:19L-22L.
5. 5. Pradhan AD, Shrivastava S, Cook NR, Rifai N, Creager MA, Ridker PM. Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk. Circulation. 2008;117:823-831. (Pubitemid 351640684)
6. 6.RidkerPM,StampferMJ,RifaiN.Novelriskfactorsforsystemicatherosclerosis: acomparisonofC-reactiveprotein,fibrinogen,homocysteine,lipoprotein(a), andstandardcholesterolscreeningaspredictorsofperipheralarterialdisease.JAMA. 2001;285:2481-2485.(Pubitemid32433842)
7. 7.KrauseBR,AuerbachBJ. Reversecholesteroltransportandfuturepharmacologicalapproaches- thetreatmentofatherosclerosis.CurrOpinInvestigDrugs.2001;2:375-381. (Pubitemid32279782)
8. 8. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300. (Pubitemid 37430562)
9. 9. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodes-Cabau J. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297: 1675-1682. (Pubitemid 46631626)
10. Griffin JH, Fernandez JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost. 2001;86:386-394.
11. 11. Brewer HB Jr. High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vase Biol. 2004;24:387-391. (Pubitemid 38326126)
12. 12.ShahPK,YanoJ,ReyesO,ChyuKY,KaulS,BisgaierCL,DrakeS,CercekB. High-doserecombinantapolipoproteinA-I(milano) mobilizestissuecholesterolandrapidlyreducesplaquelipidandmacrophagecontentin apolipoproteine-deficientmice.Potentialimplicationsforacuteplaquestabilization. Circulation.2001;103:3047-3050.(Pubitemid32587849)
13. 13. Nicholls SJ, Cutri B, Worthley SG, Kee P, Rye KA, Bao S, Barter PJ. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vase Biol. 2005;25:2416-2421. (Pubitemid 41552664)
14. Ibanez B, Vilahur G, Cimmino G, Speidl WS, Pinero A, Choi BG, Zafar MU, Santos-Gallego CG, Krause B, Badimon L, Fuster V, Badimon JJ. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol. 2008;51:1104-1109.
15. 15. Vink A, Schoneveld AH, Poppen M, de Kleijn DP, Borst C, Pasterkamp G Morphometric and immunohistochemical characterization of the intimai layer throughout the arterial system of elderly humans. J Anat. 2002;200:97-103. (Pubitemid 34285293)
16. 16.LerchPG,FortschV,HodlerG,BolliR. Productionandcharacterizationofareconstitutedhighdensitylipoproteinfortherape uticapplications.VoxSang.1996;71:155-164.(Pubitemid26341155)
17. 17.O'BrienKD,AllenMD,McDonaldTO,ChaitA,HarlanJM,FishbeinD,McCartyJ, FergusonM,HudkinsK,BenjaminCD,etal.Vascularcelladhesionmolecule- 1isexpressedinhumancoronaryatheroscleroticplaques. Implicationsforthemodeofprogressionofadvancedcoronaryatherosclerosis. JClinInvest.1993;92:945-951.(Pubitemid23262418)
18. 18.HwangSJ,BallantyneCM,SharrettAR,SmithLC,DavisCE,GottoAMJr,BoerwinkleE. CirculatingadhesionmoleculesVCAM-1,ICAM-1,andE- selectinincarotidatherosclerosisandincidentcoronaryheartdiseasecases: theAtherosclerosisRiskInCommunities(ARIC)study.Circulation.1997;96:4219-4225. (Pubitemid28007447)
19. 19. Morisaki N, Saito I, Tamura K, Tashiro J, Masuda M, Kanzaki T, Watanabe S, Masuda Y, Saito Y. New indices of ischemic heart disease and aging: studies on the serum levels of soluble intercellular adhesion molecule-1 (ICAM-1) and soluble vascular cell adhesion molecule-1 (VCAM-1) in patients with hypercholesterolemia and ischemic heart disease. Atherosclerosis. 1997;131:43-48. (Pubitemid 27240095)
20. 20. Raj T, Kanellakis P, Pomilio G, Jennings G, Bobik A, Agrotis A. Inhibition of fibroblast growth factor receptor signaling attenuates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vase Biol. 2006;26:1845-1851. (Pubitemid 44305339)
21. 21. Kalinina N, Agrotis A, Antropova Y, Ilyinskaya O, Smirnov V, Tararak E, Bobik A. Smad expression in human atherosclerotic lesions: evidence for impaired TGF-beta/Smad signaling in smooth muscle cells of fibrofatty lesions. Arterioscler Thromb Vase Biol. 2004;24:1391-1396. (Pubitemid 39050430)
22. 22.TakakuM,WadaY,JinnouchiK,TakeyaM,TakahashiK,UsudaH,NaitoM,KuriharaH, YazakiY,KumazawaY,OkimotoY,UmetaniM,NoguchiN,NikiE,HamakuboT,KodamaT. Aninvitrococulturemodeloftransmigrantmonocytesandfoamcellformation. ArteriosclerThrombVaseBiol.1999;19:2330-2339.(Pubitemid29477833)
23. Kanellakis P, Slater NJ, Du XJ, Bobik A, Curtis DJ. Granulocyte colonystimulating factor and stem cell factor improve endogenous repair after myocardial infarction. Cardiovasc Res. 2006;70:117-125.
24. 24. Sviridov D, Chin-Dusting J, Nestel P, Kingwell B, Hoang A, Olchawa B, Starr J, Dart A. Elevated HDL cholesterol is functionally ineffective in cardiac transplant recipients: evidence for impaired reverse cholesterol transport. Transplantation. 2006;81:361-366. (Pubitemid 43255720)
25. Ross R. The Pathogenesis of Atherosclerosis. In: Braunwald E, ed. Heart Disease. A Textbook of Cardiovascular Medicine. Philadelphia, Pa: WB Saunders; 1997:1105-1126.
26. 26.RongJX,LiJ,ReisED,ChoudhuryRP,DanskyHM,ElmalemVI,FallonJT,BreslowJL, FisherEA.Elevatinghigh-densitylipoproteincholesterolinapolipoproteinE- deficientmiceremodelsadvancedatheroscleroticlesionsbydecreasingmacrophagean dincreasingsmoothmusclecellcontent.Circulation.2001;104:2447-2452. (Pubitemid33108379)
27. Lavie CJ, Milani RV. Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era. J Am Coll Cardiol. 2008;51:56-58.
28. 28. Nicholls SJ, Dusting GJ, Cutri B, Bao S, Drummond GR, Rye KA, Barter PJ. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation. 2005;111:1543-1550. (Pubitemid 40470651)
29. 29. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Luscher TF, Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399-1402. (Pubitemid 34263266)
30. 30. Bisoendial RJ, Hovingh GK, Levels JH, Lerch PG, Andresen I, Hayden MR, Kastelein JJ, Stroes ES. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low highdensity lipoprotein. Circulation. 2003;107:2944-2948. (Pubitemid 36736637)
31. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
32. Tolle M, Pawlak A, Schuchardt M, Kawamura A, Tietge UJ, Lorkowski S, Keul P, Assmann G, Chun J, Levkau B, van der Giet M, Nofer JR. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vase Biol. 2008;28:1542-1548.
33. 33. Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M, Herrgott I, Mersmann J, Larmann J, Hermann S, Stypmann J, Schober O, Hildebrand R, Schulz R, Heusch G, Haude M, von Wnuck Lipinski K, Herzog C, Schmitz M, Erbel R, Chun J, Levkau B. High-density lipoproteins and their constituent, sphingosine-1- phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation. 2006;114:1403-1409. (Pubitemid 44454560)